The Observation Of Clinical Effect Of Passive Immunization Of HBIG Blocking The Hepatitis B Virus To The Maternal-Infantile Transimission Action

The hepatitis B virus infection of baby and infant is mostlytransmitted by maternal-infantile transmissin of HBV infection. Whenbaby and infant will be human beings, some of them attack a high riskof liver failure;Other will be HB positive replication. Furthermore,their symptoms are not intensively monitored, so they neglect theirbody and cure effectively, when they grow up, Some of them withinteruterine infection are liver cirrhesis,liver fiberization and evenliver cancer. If they are hepatitis B virus infection patients, theiremotional press and economical burten are sure of serious largely.From 1980s, all of infants be given vaccination against hepatitis B, Alot of clinical study that comes from all over the world mostly provedHBV Vaccinc is safe and effective. Howerer, 10%~20% of them areinfected the hepatitis B virus. Medical scholars explore some effectivemedcines and methods all the time, but they can't find them so far. The Study on the mechanism of passive immunization ofhepatitis B immuneglobulin blocking the hepatitis B virus to thematernal-infantile transmission action are major. HBIG is a passiveimmunization, and it is produced by the blood that people have everbeen given vaccination against HB virus. today, a lot of doctor believeit is effective that passive immunization with HBIG of pregnantwoman can block maternal-infantile transimission of HBV infection.and HBIG is no side effect.This study on the mechanism of passive immunization ofhepatitis B immuneglobulin blocking the hepatitis B virus to thematernal-infanterle transmissin action. If the HB positive pregnantwomen are injected with HBIG at 28th, 36th week and their newbornsalso are injected with HBIG at the date of birth and two week old, thusthe baby and infant are looked as the prophylaxis group. The goal is toobserve the detection rate of antis-HBs and antis-HBs (>10mIU/ml)and the detection rate of serologic HBV marks of cord blood and veinblood of 7 months and one year old.The subjects of this study from chang chun Obstetric andGynecologic Hospital and China-Japan Union Hospital of Ji LinUniversity during form 2004 January to 2005 March are the HBpositive pregnant women and their babys and infants. In early or late,randomized controlled trial, 83 cases of HB positive pregnant womenwere divide into two groups. In the prophy laxis group, 42cases areinjected by doctor with HBIG at 28th. 32th. 36th Week duringpregnancy (200IU per time) and their newborns are injected withHBIG at date of birth and two weeks old (200IU per time). In thecontrol group, 41 cases are flown-up and each of them is not passiveimmunization. At the same time, but the infants of two group areinjected with HB vaccinc by "0. 1. 6"project. The babys and infants oftwo groups are observed from newborns to one year old. The doctorscollect blood samples. at date of birth. seven months old and a yearold. By using diantibody sanwith enzyne linked immaosorbant assay(DAS-ELISA) and fluorenscen quantitative polynerase reaction(FOR-PCR) the HBV marker. The results display, in the prohy laxisgroup and the control group, the vertical transmission incidence of thenewborns was lower than those in control group (P<0.05),respectively 5%, 21.05%, there was significant different between them.The vertical thransmission incidence of the seven months old waslower than those in control group, but there wasn't significantdifference between them;The vertical transmission ineidence of theone year old was lower than those in control groups, and there wassignificant difference between them. The detection rate of anti-HBS ofprophylaxis group was significantly higher than these in control group(P<0.05), and there was significant, different between them. At aspecified future date, Seven of two groups cases are the hepatitis Bvirus infection, but their liver function tests are normal, eight of twogroups are cases with anti-HBs(<10mIU/ml), and they are givenvaccinc again.Sum up, the conclusion is that passive immunization with HBIGof pregnant woman can block maternal-infantile transmission of HBVinfection effectively, including, HBIG reduce incidence of the verticaltransmittedby maternal-infantile transmission of HBV infection andenhance the detection rate of antis-HBs(>10mIU/ml). So the pregnantwomen should be checked regularly HBVM and HBV-DNA. If theyare the pregnant women with HB virus infection, they should beinjected HBIG in time.Today, there are not more effective medicines and methods and toreduce the rate of intrantorine infection. especially, this study suggestHBIG is no by-effect, furethermore, HBIG is effective, therefore,HBIG should be recommend.